bluuebunny/crossref_metadata_2025 huggingface dataset:
904-P: Glycemic Improvement in Patients with Type 2 Diabetes under Treatment with a Fixed-Dose Combination Glimepiride/Vildagliptin/Metformin with Failure to Previous Dual Therapy
Authors: RIOS-BRITO KEVIN F. , RODRIGUEZ-ROCANDIO KARLA E. , SANDER-PADILLA JOSE G. , LUGO-SÁNCHEZ LAURA A. , ROMERO YULIA , ARGUEDAS MARÍA M. , MORA JULIO C. , RODRIGUEZ-VAZQUEZ ILEANA C. , FLORES-HUANOSTA DIANA , GONZALEZ-CANUDAS JORGE
Published: June 2024

Introduction & Objective: Failure to type 2 diabetes (T2D) treatment leads to complications. Combination therapies with different mechanisms of action are often required to achieve glycemic goals. This study aimed to evaluate the efficacy and safety of glimepiride/vildagliptin/metformin in patients with T2D.

Methods: A multicenter, randomized, double-blind study was conducted. Patients over 18 years with previous dual therapy and inadequate glycemic control (glycated hemoglobin (HbA1c) ≥7.0% and ≤11.0%) were included. Participants were initially treated with glimepiride 1/vildagliptin 50/metformin 500 mg. At 45 days, HbA1c was evaluated, patients with efficacy (reduction of HbA1c ≥0.3%) continued with the same treatment, and those with no response were randomly assigned to (2/50/1000 mg) or (4/50/1000 mg). The primary endpoint was efficacy at 90 days.

Results: We enrolled 113 participants (mean age 53 years, HbA1c 9.5 ± 1.0%), three previous therapies were described: Biguanide/Sulfonylurea (62.8%), Biguanide/DPP-4 inhibitors (29.2%) and Biguanide/SGLT2 inhibitors (8.0%). At 45 days, 65.8% of patients showed a positive response, independently of their previous therapy, and 34.2% were escalated. %HbA1c differences were reported: Biguanide/Sulfonylurea (9.5 to 8.7, p=0.001), Biguanide/DPP-4 inhibitors (9.4 to 8.3, p=0.001), and Biguanide/SGLT2 inhibitors (9.3 to 8.6, p=0.040). Over 90 days of follow-up, 107 patients completed the study and 72 achieved a reduction of HbA1c ≥0.3% (63.7%). Three mild hypoglycemic events were reported with the starting dose.

Conclusion: Glimepiride/vildagliptin/metformin therapy improved glycemic control in patients with T2D and previous dual combination failure, this treatment was well tolerated with a low incidence of hypoglycemia.

Disclosure

K.F. Rios-Brito: Employee; Laboratorios Silanes S.A. de C.V. K.E. Rodriguez-Rocandio: Employee; Laboratorios Silanes S.A. de C.V. J.G. Sander-Padilla: Employee; Laboratorios Silanes. L.A. Lugo-Sánchez: Employee; Laboratorios Silanes S.A. de C.V. Y. Romero: Employee; Laboratorios Silanes. M.M. Arguedas: Employee; Laboratorios Silanes S.A. de C.V. J.C. Mora: Employee; Laboratorios Silanes. I.C. Rodriguez-Vazquez: Employee; Laboratorios Silanes S.A. de C.V. D. Flores-Huanosta: Employee; Laboratorios Silanes. J. Gonzalez-Canudas: Employee; Silanes SA CV.

Funding

Laboratorios Silanes S.A. de C.V.
92-OR: Defining Type 1 Diabetes Endtypes
Authors: BEDRAT AMINA , PANT TARUN , JIA SHUANG , ROETHLE MARK , TRUCHAN NATHAN A. , CHEN YI-GUANG , LIN CHIEN-WEI , HESSNER MARTIN
Published: June 2024

To explore T1D heterogeneity, the existence of endotypes, and their possible differential responses to immunotherapy administered at clinical onset, we studied 566 TrialNet clinical trial participants (MMF-DZB, anti-CD20; GAD-alum; CTLA4-Ig; Canakinumab; ATG-GCSF). A bioassay, where participant serum is used to induce transcription in healthy mononuclear cells, and unsupervised cluster analyses were used to identify 2 major groups (Gp1 and Gp2).Proportional analyses of subjects <18 years found Gp1 enriched with participants <14 years old (p=0.03); further Gp1 placebo arm participants exhibited a more rapid C-peptide rate of decline (<-0.15, p=0.02). Pathway analysis of transcriptomic data predicted inflammatory bias in Gp1, that was confirmed by detection of elevated plasma IFNγ, TNFα, and IL-6 levels (p<0.01), and higher memory T-cell abundances. When assessing response to therapy, Gp1 anti-CD20-treated participants exhibited a higher mean C-peptide compared to placebos at 6, 12 and 24 months post-onset (meta-p=0.002 vs 0.27 in Gp2) and a greater delay in the post-onset decline of baseline stimulated C-peptide (11.2 vs 5.4 months). In contrast, Gp2 CTLA4-Ig-treated participants exhibited a higher mean C-peptide compared to placebos at 6, 12, 18 and 24 months (meta p=2e-4 vs. 0.24 in Gp1) and a greater delay in the decline of baseline stimulated C-peptide (8.7 vs 5.8 months). Both Gp1 and Gp2 benefited from ATG treatment, respectively showing 9.5 and 6.7 month delays in the decline in baseline stimulated C-peptide compared to their corresponding placebos. Weighted correlation network analyses of transcriptomic data suggested that varying degrees of immunomodulation occurred in all 6 trials, including those not showing overall efficacy. In line with that observation, Gp2 canakinumab-treated participants showed a 3.4-month delay in the decline in baseline stimulated C-peptide compared to placebos. These data support the existence of two T1D endotypes that exhibit distinct immune phenotypes and therapeutic responsiveness.

Disclosure

A. Bedrat: None. T. Pant: None. S. Jia: None. M. Roethle: None. N.A. Truchan: None. Y. Chen: None. C. Lin: None. M. Hessner: None.

Funding

R01DK121528
927-P: Sodium–Glucose Cotransporter 2 Inhibitors Use during Ramadan in People with Type 1 Diabetes—Observational Study
Authors: ALOZAIRI EBAA S. , IRSHAD MOHAMMAD , SOJAN LITTY G. , ALROUDHAN DHERAR , TAGHADOM ETAB , ALKANDARI JUMANA
Published: June 2024

Introduction & Objective: Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a novel class of anti-hyperglycemic agents with added benefit of renal protection. Their use in type 1 diabetes is limited. During Ramadan Muslims fast from sunset to sunrise, abstaining from both food and drink which increase the potential risk of dehydration and adverse effects. This study aimed to compare glycemic metrics and adverse events in fasting and non-fasting people with Type 1 Diabetes (T1D) using SGLT2 inhibitors during Ramadan.

Methods: In this prospective observational study, twenty-five people with T1D (mean age± SD: 40.4± 10.4 years, HbA1c: 7.8%± 1.2%) were divided into fasted (n=12) and non-fasted (n=13) groups. Participants received a stable dose of SGLT2 inhibitors before fasting and using continuous glucose monitoring (CGM) device. Outcomes measured differences in percentage time spent in the target range (3.9-10 mmol/L), hypoglycemic range (<3.9 mmol/L), hyperglycemic range (>10 mmol/L), glucose variability (CV%), and diabetes ketoacidosis between groups. All people underwent structured education for the safe use of SGTL2 inhibitors.

Results: The mean fasting duration was 26.2± 3.5 days (range: 18-29 days). No significant differences were observed in the target range (-8.0± 11.2% vs. -0.6± 10.3%), hyperglycemic range (8.2± 11.5% vs. 0.3± 10.7%), hypoglycemic range (-0.2 ±2.7% vs. 0.3± 10.7%) and glycemic variability (1.0± 2.6% vs. -0.5± 5.4%) between fasting and non-fasting groups using SGLT2 inhibitors. No severe hypoglycemia, diabetic ketoacidosis (DKA), or hospitalizations occurred in either group during the fasting period.

Conclusions: The use of SGLT2 inhibitors in people with T1D during Ramadan fasting appears safe and well-tolerated, with no reported adverse events for people undergoing structured education. However, further clinical trials are necessary to validate these findings.

Disclosure

E.S. Alozairi: None. M. Irshad: None. L.G. Sojan: None. D. Alroudhan: None. E. Taghadom: None. J. AlKandari: None.

Funding

Kuwait Foundation for the Advancement of Sciences (KFAS), Kuwait
937-P: Efficacy and Safety of SGLT2i vs. Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes—A Systematic Review and Meta-analysis
Authors: MA YUHANG , LIN YI , DING XIAOYING , PENG YONGDE
Published: June 2024

Introduction & Objective: The combination of metformin (met) with other oral antidiabetic drugs (OADs) like sodium-glucose cotransporter-2 inhibitors (SGLT-2i) is recommended by international guidelines for type 2 diabetes mellitus treatment. This systematic literature review (SLR) and meta-analysis (MA) compared the efficacy and safety specifically of dual therapy with SGLT-2i versus other OADs as add-on to met.

Methods: An update to a 2016 SLR was conducted to identify randomized controlled trials (RCTs) comparing dual therapies of OADs + met. Searches of MEDLINE, Embase, the Cochrane Library, recent congresses and SLR bibliographies were conducted in May 2023. RCTs were assessed using the Cochrane Risk of Bias tool. MAs employing random effect models compared change in haemoglobin A1c (HbA1c) and adverse events with SGLT-2i versus other OADs as add-on to met at Week 52.

Results: A total of 23 RCTs comprising of 11,911 patients on oral met-containing dual therapies (SGLT-2is, dipeptidyl peptidase-4 inhibitors, oral glucagon-like peptide-1 receptor agonists and sulfonylureas) were included. The mean difference (MD) in change from baseline of HbA1c with SGLT-2i + met versus other OADs + met was comparable (MD 0.01, 95% confidence interval [CI] -0.16-0.18). In terms of safety, SGLT-2i + met had a significantly lower risk of hypoglycaemia (risk ratio [RR] 0.27, 95% CI 0.09-0.84) and lower risk of myocardial infarction (MI) (RR 0.58, 95% CI 0.16-2.07) than other OADs + met. However, risk of urinary tract infection (UTI) was higher (RR 1.22, 95% CI 0.94-1.58).

Conclusion: Compared with other OADs + met dual therapies, SGLT-2i + met exhibited noninferior efficacy and significantly reduced risk of hypoglycaemia while risks of MI and UTI were not significantly different. Results from this study reinforce the recommendation of dual therapy in international guidelines, depending on patients’ treatment goals and risk profiles.

Disclosure

Y. Ma: None. Y. Lin: None. X. Ding: None. Y. Peng: None.
962-P: Assessment of Hybrid Closed-Loop Impact upon Glycemic Control, Weight, and Retinopathy
Authors: GIBB FRASER W. , FORBES SHAREEN , DOVER ANNA R. , STIMSON ROLAND H. , LYALL MARCUS
Published: June 2024

Background: We sought to assess real-world outcomes in adults with type 1 diabetes commenced on hybrid closed loop (HCL).

Methods: Observational study of 254 adults following conversion from CSII to HCL in a secondary care setting. Outcomes included change in CGM metrics, HbA1c, weight and eye disease.

Results: Mean age was 41±14 years (70% female) and diabetes duration was 22±12 years. 102 were on Tandem CIQ, 79 on Medtronic 780G, 57 on Omnipod 5 and 16 on CAM APS. HbA1c fell by 0.64% (p <0.001, mean follow up 467 days). Where HbA1c >7.5% at baseline, the fall in HbA1c was 0.91% (p <0.001). HbA1c <7.5% increased from 39% to 65% and HbA1c >9% decreased from 12% to 5% (p <0.001). CGM metrics are presented below. There was no significant change in weight (+0.1 kg, p = 0.610) over a mean follow up of 356 days. Those with a >5% improvement in TIR experienced greater weight gain (+0.6kg vs -1.2kg, p = 0.012). Of 113 individuals with routine retinal screening data, only 17 experienced any degree of worsening and this was not associated with change in TIR or HbA1c (but was associated with low baseline TIR [p = 0.03]). In a logistic regression model, lower age and higher HbA1c were associated with superior TIR response to HCL (but gender, BMI and socioeconomic deprivation were not).

Conclusion: HCL is associated with substantial glycemic benefits - particularly in those with highest baseline HbA1c. The extent of weight gain and EWDR appears to be small.

Disclosure

F.W. Gibb: Speaker's Bureau; Abbott. Advisory Panel; Insulet Corporation. Speaker's Bureau; Novo Nordisk. S. Forbes: None. A.R. Dover: None. R.H. Stimson: None. M. Lyall: None.
97-OR: Preclinical Characterization of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator
Authors: PATTON DANIEL , PHAM MINH , GARDELL JENNIFER L. , BOSTER DANIEL , JULIEN SUSAN , MCMAHAN CATHERINE , CRANE COURTNEY , SWIDEREK KRISTINE M.
Published: June 2024

Introduction and Objectives: In healthy individuals, activation and expansion of CD8 regulatory T cells (CD8 Treg) leads to selective killing of pathogenic CD4 T cells without broad immunosuppression. In patients with autoimmunity, CD8 Treg appear dysfunctional, allowing pathogenic CD4 T cell expansion and downstream inflammatory events, causing damage to healthy tissues. MTX-101 is a bispecific CD8 Treg modulator targeting CD8 and KIR2DL(1/2/3), co-expressed on CD8 Treg. MTX-101 targets CD8 Treg to restore their function and reduce inflammation without unwanted immune cell activation or global immune suppression. By targeting a root cause of CD4-driven autoimmune diseases, our data suggest that MTX-101 is a promising CD8 Treg-specific therapeutic to restore immune balance for the treatment of Type 1 Diabetes (T1D).

Methods: We evaluated MTX-101 binding, mechanism of action, and specificity in vitro using human PBMCs and in vivo using a human CD4 T cell-driven GVHD model. Pharmacology and early tolerability were evaluated in humanized CD34+-engrafted NSG(IL-15Tg) mice.

Results: MTX-101 increased the activation and functions of CD8 Treg without activating other immune cells or affecting global immune responses in vitro, and improved outcomes in the acute GVHD model. In Balb/c and humanized mice, MTX-101 pharmacokinetics were consistent with antibody-like molecules. In humanized mice, MTX-101 bound CD8 Treg in peripheral blood and terminal tissues, with no resulting activation of immune cells. No induction of proinflammatory serum cytokines were observed following MTX-101 dosing at concentrations up to 50 mg/kg.

Conclusion: MTX-101 restores CD8 Treg functions and may provide durable resistance to autoimmune disease progression.

Disclosure

D. Patton: None. M. Pham: None. J.L. Gardell: Employee; Mozart Therapeutics. D. Boster: Employee; Mozart Therapeutics. S. Julien: Employee; Mozart Therapeutics. C. McMahan: None. C. Crane: Employee; Mozart Therapeutics. K.M. Swiderek: None.

Funding

Mozart Therapeutics
984-P: Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre System Initiation in People with Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy in France
Authors: GUERCI BRUNO , LEVRAT-GUILLEN FLEUR , DETOURNAY BRUNO , VICAUT ERIC , DEPOUVOURVILLE GERARD , EMERY CORINNE , RIVELINE JEAN-PIERRE
Published: June 2024

Introduction: People with T2D treated with oral insulin-secretagogues are at risk for acute diabetes events (ADEs), including DKA and hypoglycemia. This study investigates the change in hospitalization rates for ADEs following initiation of FreeStyle Libre® system (FSL), in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin.

Methods: Retrospective study of the French national SNDS claims database identified people with T2D treated with insulin-secretagogues without insulin and a FSL initiation date between 01/Aug/2017 to 31/Dec/2018. Data for the 12 months before and after FSL initiation were included. Hospitalizations were identified using ICD-10 codes for: DKA; hyperglycemia; hypoglycemic events; comas.

Results: 4,962 people with T2D on oral insulin-secretagogue drugs initiated FSL during the selection period. Of these, 8.7% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 2.4% in the year after initiation (Fig 1), a reduction of 72%. The reduction in ADEs was driven by -81% fewer admissions for DKA or hyperglycemia.

Conclusions: This study suggests that use of the FSL system is associated with reduced hospital admissions for ADEs in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin.

Disclosure

B. Guerci: Advisory Panel; Abbott Diagnostics, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Bayer Inc., Medtronic, Insulet Corporation, Dexcom, Inc., Boehringer-Ingelheim. F. Levrat-Guillen: Employee; Abbott. B. Detournay: Advisory Panel; AstraZeneca. Consultant; Abbott, AstraZeneca, Novo Nordisk, Sanofi, CEMKA, CERBA expert. E. Vicaut: Consultant; Abbott, Boston Scientific Corporation, COLOPLAST. G. DePouvourville: Advisory Panel; Abbott, Alexion Pharmaceuticals, Inc., AstraZeneca, Astellas Pharma Inc., Bayer Inc., Boehringer-Ingelheim, Bristol-Myers Squibb Company, Biogen. Research Support; GlaxoSmithKline plc. Advisory Panel; IQVIA Inc., Lundbeck, Janssen Pharmaceuticals, Inc., Moderna, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company Limited, Viatris Inc., Edwards Life Sciences, UCB, Alexion Pharmaceuticals, Inc., DBV-Technology, EFPIA. C. Emery: None. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca.

Funding

Abbott
989-P: The Effect of Continuous Glucose Monitoring on Postoperative Glucose Control in People with Type 2 Diabetes Mellitus Undergoing Coronary Artery Bypass Grafting—A Randomized Clinical Trial
Authors: SON HEEJUN , HO SOHN SUK , AH KIM HYUN , JEE CHOE HUN , LEE HYUNSUK , SEUNG JUNG HYE , MIN CHO YOUNG , SOO PARK KYONG , YOUNG HWANG HO , HEON KWAK SOO
Published: June 2024

Introduction & Objective: Effective glycemic control following cardiac surgery improves overall clinical outcomes, and continuous glucose monitoring (CGM) is a valuable tool in achieving this objective. We investigated the effect of CGM on postoperative glycemic control in patients with diabetes after coronary artery bypass grafting (CABG).

Method: In this randomized clinical trial involving adults with type 2 diabetes undergoing CABG, all participants utilized real-time CGM (Dexcom G6) after scheduled CABG, and received a basal bolus insulin regimen. The subjects were randomly assigned to either a test group utilizing CGM for glycemic control, or a control group with blinded CGM measures, relying on point-of-care measures. The primary outcome was the percentage of time in range (TIR) of blood glucose between 70-180 mg/dL, as measured by CGM.

Results: Of total 96 subjects, 49 were in the test group and 47 in the control group. CGM was applied for 5.9 ± 2.0 days. Participants had a mean age of 68.9 ± 9.3 years, and baseline glycated hemoglobin was 7.2 ± 0.9 %. The least squares (LS) mean ± standard error of TIR was 58.9 ± 2.7%, 50.2 ± 2.8% in the test and control group, respectively. TIR was significantly higher in the test group than in the control group when adjusted with age, sex, body mass index, and baseline glycated hemoglobin (LS mean difference, 8.3%; 95% confidence interval, 0.4-16.3; p=0.041). Time above range and mean glucose levels were also significantly lower in the test group than in the control group. No differences in time below range, coefficient of variation, and hypoglycemic event rate were observed between the two groups.

Conclusion: In this randomized clinical trial, Dexcom G6 CGM has enhanced glycemic control without increasing the risk of hypoglycemia. Given the benefits of effective glycemic control on perioperative outcomes, CGM may be helpful in managing type 2 diabetes after CABG.

Disclosure

H. Son: None. S. Sohn: None. H. Kim: None. H. Choe: None. H. Lee: None. H. Jung: Research Support; Novo Nordisk. Y. Cho: None. K. Park: None. H. Hwang: None. S. Kwak: Employee; SNUH Venture.
99-OR: SLC7A2-Dependent Arginine Transport in α-Cells Signals Arginine tone to Regulate Insulin Secretion
Authors: STANLEY JADE , DEAN DANIELLE , SELLICK KATELYN
Published: June 2024

Diabetes results from a decline in pancreatic β-cell function with simultaneous hyperglucagonemia, resulting in hyperglycemia. Over 60 years ago, arginine was identified as a potent secretagogue of glucagon secretion, yet the mechanisms behind this are not thoroughly elucidated. Recently, we found that the cationic amino acid transporter, SLC7A2/CAT2 is the most highly expressed amino acid transporter in human pancreatic α-cells and three-fold higher in α-cells than it is in β-cells and other islet cell types in both mouse and human islets. We showed that global loss of SLC7A2 in mice resulted in impaired arginine stimulated glucagon and insulin secretion. However, based on the expression pattern of SLC7A2, we predicted β-cells might be poor arginine sensors. To assess the role of α-cell expression of SLC7A2 arginine-stimulated hormone secretion, we made either α-cell or β-cell specific Slc7a2-/- (α7A2KO;β7a2KO) mice. Hormone levels were measured in 6-hour fasted and arginine challenged mice (2g/kg via intraperitoneal injection). Blood glucose, glucagon, and insulin levels were not significantly different after fasting in α7A2KO, β7a2KO, and Slc7a2f/f cre- (7a2f/f) control mice. As expected, 15 minutes after arginine bolus, α7A2KO mice had significantly lower arginine stimulated glucagon levels compared to β7a2KO and 7a2f/f mice (arginine-stimulated glucagon - β7a2KO 102.4 ± 36.8 pM vs. α7A2KO 14.1 ± 18.7 pM vs. 7a2f/f 103.8 ± 76.5; n=6-11 p<0.001). However surprisingly, β7a2KO mice had similar insulin levels to control mice, while α-cell specific α7A2KO mice had a two fold reduction in arginine stimulated insulin secretion (arginine-stimulated insulin - β7a2KO 424.1 ± 172.3 pM vs. α7A2KO 158.1 ± 57.5 pM vs. 7a2f/f 368.2 ± 212.4; n=6-11 p<0.001). In summary, we found that α-cells act as the predominant arginine sensor in islets communicating arginine tone to neighboring β-cells perhaps through proglucagon-derived peptides or other α-cell products.

Disclosure

J. Stanley: None. D. Dean: None. K. Sellick: None.

Funding

National Institutes of Health (R01DK132669, R01DK130296, F31DK134158, and P30DK020593)
990-P: Developing a Breath-Based Glucose Estimation Device for People with Type 2 Diabetes
Authors: GOURDY PIERRE , CAZALS LAURENT , FRANÇOIS-MARSAL CLARISSE , BLANC CALVO SOPHIE , ISZ SANDRINE , LEPAGE BENOÎT , FLACKE FRANK
Published: June 2024

Introduction and Objectives: BOYDSense is developing a breath-based monitoring system for chronic conditions starting with glucose monitoring for people with type 2 diabetes (T2D). These are results of a proof-of-concept study to evaluate the correlation of Volatile Organic Compounds (VOCs) in exhaled human breath with SMBG glucose values. The aim of this study, performed at CHU-Toulouse, was to develop a first glucose estimation algorithm for the BOYDSense breath-based technology and to assess its performance.

Methods: The study combined 2 successive phases and enrolled in total 130 subjects with T2D on OAD and/or GLP-1 and/or basal insulin. In phase 1 100 subjects underwent a standardized meal challenge and, at each sampling point, a reference glucose value (venous blood) and 3 breath data-sets were collected to train the algorithm supported by AI. In phase 2 the developed algorithm was used to display glucose estimates. 30 subjects underwent the same procedure as described above and also SMBG readings were taken at the sampling points. The study center collected the data and conducted the data analysis.

Results: In phase 2, 630 data-pairs (breath/SMBG) were collected. For the complete dataset, a Consensus Error-Grid-Analysis (C-EGA) for T2D was calculated. zone A contained 79.7% and zone A+B 99.7% of all readings. Only 2 readings were in zone C. A comparison of the C-EGA of the 3 breath strokes at each sampling point showed no obvious differences between the strokes (zone-A/zone-A+B): breath-1 80.0%/99.5%, breath-2 78.1%/100%, breath-3 81.0%/ 99.5% The overall MARD was estimated to 19.6%. The auto-sampling prototypes demonstrated a high reliability (99.9%).

Conclusion: The prospective performance of the first algorithm iteration of the BOYDSense breath analyzer showed in comparison to real-life SMBG readings very promising results towards a new glucose estimation system supporting people with T2D. The high reliability speaks to an already advanced stage of the hardware development.

Disclosure

P. Gourdy: Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Research Support; Novo Nordisk A/S. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Advisory Panel; Pfizer Inc., Bayer Inc. Research Support; BoydSense. Speaker's Bureau; Amarin Corporation, AbbVie Inc., Boehringer-Ingelheim. Advisory Panel; Boehringer-Ingelheim, AstraZeneca. L. Cazals: None. C. François-Marsal: None. S. Blanc Calvo: None. S. Isz: None. B. Lepage: None. F. Flacke: Consultant; BOYDSense SAS, Sinocare Meditech Inc., embecta.
994-P: Real-World Evaluation of the Implantable 180-Day Eversense E3 CGM System
Authors: TWEDEN KATHERINE S. , ROMAROWSKI BEN , MDINGI COLLEEN , KAUFMAN FRANCINE R.
Published: June 2024

Background: The 180-day implantable Eversense E3 CGM System was commercialized in 2022 for adults with diabetes. This is the first real-world assessment of the 180-day E3 System in patients using open-loop insulin regimens.

Methods: Sensor glucose (SG) data obtained from the Eversense Data Managment System (DMS) for the first 1000 users in the US were used to evaluate CGM metrics. Twenty-four-hour transmitter wear time, mean SG and glycemic variability metrics, glucose management indicator (GMI), and percent in glycemic ranges were calculated over 180 days. Age, type of diabetes and gender were self-reported.

Results: The first 1000 real-world E3 CGM Systems were inserted in users of mean age 50 yrs., 57.5% male, 40.6% T1D, 28.2% T2D and 31.2% not reported. DMS provided mean 41,584±9309 CGM readings over 180 days per user. Mean values of the CGM metrics were 160.6 mg/dL for SG, 52.9 mg/dL for SD, 0.33 for CV, and 7.15% for GMI (Table). The %SG in the various glycemic ranges was as follows: 0.94% (<54 mg/dL), 3.3% (<70 mg/dL), 64.6% (≥70 to 180 mg/dL), 32.1% (>180 mg/dL) and 9.9% (>250 mg/dL). Median transmitter wear time was 83.0%. Percent of users achieving recommended glucose goals was promising with at least 70% achieving hypoglycemia targets.

Conclusion: This real-world evaluation of the Eversense E3 CGM System used with open-loop insulin regimens demonstrated that Eversense assists patients in effectively managing diabetes.

Disclosure

K.S. Tweden: Employee; Senseonics Inc. B. Romarowski: Employee; Senseonics Inc. C. Mdingi: Employee; Senseonics. F.R. Kaufman: Employee; Senseonics. Consultant; Twin Health.
Natural Radiance Unveiled: A Comprehensive Review of Herbal Cosmetics and their Transformative Effects
Authors: K* Dudhat
Published: June 2024

The use of herbal cosmetics has gained popularity due to their natural composition and perceived benefits over synthetic products. This comprehensive review explores the transformative effects of herbal cosmetics on skin, hair, nails, and oral hygiene. The benefits of using natural cosmetics include their safety, suitability for all skin types, lack of animal testing, absence of negative side effects, and affordability. Cosmeceuticals, a combination of cosmetics and pharmaceuticals, are also discussed, highlighting their various mechanisms of action and examples of active ingredients. The classification of herbal cosmetics based on dosage form and the body part to be applied on is presented, along with specific examples of herbal ingredients used in skin care, hair care, and oral care products. The study of drugs used in cosmetics is examined, featuring plants such as soapnut, amla, henna, hibiscus, tea, aloe, and liquorice. This review provides valuable insights into the world of herbal cosmetics and their potential in enhancing beauty and well-being.
Evaluation of Coiled Tubing Limitations to Drill Out Frac Plugs
Authors: Alagoz Ekrem
Published: June 2024

This paper examines the efficacy of utilizing coiled tubing technology for the drilling out of frac plugs in the oil and gas industry. While coiled tubing offers advantages such as speed, efficiency, and reduced rig time, its application is not without limitations. Mechanical constraints, hydraulic challenges, and operational issues can impede the effectiveness of coiled tubing in frac plug removal. Through an analysis of these limitations, accompanied by real-world case studies and examples, this paper highlights the need for mitigation strategies and technological advancements. It concludes with recommendations for future research and development efforts aimed at optimizing the use of coiled tubing in this critical aspect of well completion operations.
Transient BEMT models and validation through a sea trial turbine platform
Authors:   , Evans Iestyn
Published: June 2024

Tidal stream turbines (TSTs) have the potential to contribute significantly to the UK energy needs. Currently, the sector is still in a primitive stage and has a relatively high levelised cost of energy compared to other renewable energy sources. A reduction in their cost can be made by improving their design through numerical modelling and physical testing. This thesis will firstly present the classical blade element momentum theory (BEMT) numerical model which is enhanced with additional features (1. foil shape and Reynolds number dependence, and 2. transient turbulence and wave flow fields), which are incorporated to improve the predictions of loads and performance of TSTs. The improvements to the BEMT numerical model are quantified and validated by comparingto empirical data from laboratory testing of five different TSTs (Magallanes ATIR, Sabella D12, IFREMER, Oxford, and Barltrop). This inclusion of the foil shape and Reynolds number dependence in the numerical model has improved the prediction of rotor loads by up to 20%, whilst the inclusion of transient turbulence and wave flow fields has allowed for simulation of TSTs in flow conditions that were not previously possible. Secondly, the thesis presents the design and testing of a 3.0m diameter TST, named remote river energy system (RRES). The BEMT numerical model was used to predict the loads on the turbine which governed its design. A laboratory test rig was built to test the power take-off and pump assemblies prior to deployment at Warrior Way, Pembrokeshire. Valuable knowledge was gained throughout the design and testing stages of the RRES which will improve future developments of TSTs. The improvements made to the BEMT numerical model and testing of the RRES will help lower the levelised cost of energy and increase the attractiveness of TSTs as generators of clean renewable energy.
Influencia de la inteligencia artificial en la educación media y superior
Authors: Zepeda Hurtado María Elena , Cardoso Espinosa Edgar Oliver , Cortés Ruiz Jésica Alhelí
Published: June 2024

El objetivo general del ensayo es analizar las concepciones teóricas de la inteligencia artificial (IA) con la finalidad de determinar sus beneficios y desafíos para docentes y estudiantes de la educación media y superior. Para ello, se ha efectuado una investigación documental de informes y artículos con un enfoque interpretativo. Específicamente, se procuró determinar cómo se puede integrar la IA en la educación para optimizar el desempeño de maestros y estudiantes. Los resultados y conclusiones obtenidos buscan incidir en aspectos como la actualización pedagógica, la equidad en el acceso a la tecnología y las consideraciones éticas, entre otros, que deben ser tenidos en cuenta en la implementación de la IA en el ámbito educativo.
Struktur Komunitas Satuan Lanskap di Lereng Gunung Slamet Jawa Tengah
Authors: Fikriyya Nabela , Silalahi Marina , Zukarnaen Rizmoon Nurul , Nisyawati Nisyawati , Helmanto Hendra , Putri Adinda Kurnia
Published: June 2024

Masyarakat Lereng Gunung Slamet memiliki pengetahuan diversifikasi satuan lanskap yang didasarkan atas fungsi, karakteristik, dan kepemilikan. Tujuan penelitian ini adalah untuk mempelajari struktur komunitas satuan lanskap yang dimanfaatkan oleh Masyarakat Lereng Gunung Slamet. Penelitian dilakukan pada bulan Juli 2019 — Januari 2020 di desa Lereng Gunung Slamet yaitu, (1) Desa Ragatunjung, (2) Desa Cipetung, dan (3) Desa Pandansari Kecamatan Paguyangan, Kabupaten Brebes. Pengumpulan data botani dilakukan dilakukan secara purposive sampling menggunakan transek kuadrat. Analisis vegetasi diolah menggunakan Indeks Nilai Penting (INP), Indeks Keanekaragaman (H’), Indeks Kekayaan (DMg), Indeks Kemerataan (e’), dan Indeks Kesamaan komunitas. Berdasarkan Analisis vegetasi ditemukan 136 spesies yang dikategorikan ke dalam 11 genus dan 55 famili. Analisis struktur komunitas dapat dilihat pada H’ berkisar antara 1,57—28,9 yang termasuk dalam kategori sedang. DMg berkisar antara 11,82 – 28,8 dan Indeks kemerataan berkisar antara 0,11—0,92. Indeks kesamaan antar satuan lanskap,  wanah dan majegan merupakan yang tertinggi yakni 62,67% yang termasuk kategori tinggi. Selanjutnya nilai Indeks kesamaan jenis lanskap yang sama antar desa, tertinggi pada lanskap majegan di Desa Cipetung dan Pandansari (45,71%.) dan wanah pada Desa Ragatunjung dan Desa Cipetung (42,86 %).
Atraumatic Restorative Treatment: An Overview and Update
Authors: Hodali Lana , Massad Nabil
Published: June 2024

Atraumatic Restorative Treatment (ART) has emerged as an essential strategy in dentistry, particularly in regions with limited resources and for patient populations facing barriers to conventional treatments. This minimally invasive approach involves gently removing caries using hand instruments and restoring cavities with materials like high-viscosity glass ionomer cement (HVGIC). This article provides a comprehensive overview of the ART technique, covering its historical development, indications, contraindications, and clinical efficacy. It highlights its versatility and potential to improve access to quality dental care worldwide.
Design of an Energy Efficient Buck Based LED Driver in DCM and CCM
Authors: Ferdous Fouzia , Hassan Mahamudul , Rahman Naimur , Hassan Touhidul , Islam Rakibul
Published: June 2024

It is the design criteria of driving LEDs at constant current and keeping the input current’s harmonics low, attaining a high power factor, and maximizing efficiency. For low power general purpose lighting buck converter can be chosen for simplicity and reduced cost. It is a difficult to improve power quality parameter like, the THD (total harmonic distortion) and power factor of ac mains. In the proposed topology, the operation for high power factor and low THD at the AC mains’ input is accomplished through buck converter operation in both discontinuous conduction mode (DCM) and continuous conduction mode (CCM) with a suitable control circuit. This paper assures constant current in both cases for suitable design of control circuit. Over voltage protection has been incorporated. To validate the LED driver circuit, simulation studies are carried out.
Messen ist Wissen - Digitalisierung in der Hafenwirtschaft
Authors: Hoogsteden Emile
Published: June 2024

Wurde Öl früher das Schwarze Gold genannt, so sind Daten das digitale Gold der Zukunft. Zukunftsfähige Häfen als leistungsfähige Umschlagszentren müssen daher die Möglichkeiten der Digitalisierung nutzen. Die Transparenz eines Hafens ist dem Informationsaustausch zu verdanken. Dieser führt zur Optimierung der Logistikkette und erhöht den Warenumschlag. Für einen Hafenbetrieb als entscheidendem Glied in der Supply Chain ist die innovationsgetriebene, beschleunigte Entwicklung neuer Konzepte und Umsatzmodelle für einen „smarten Hafen“ absolut notwendig.
Digitale Prozesskette von der Planung bis zum Fahrer
Authors: Krüger Christian , Schaffert Marc
Published: June 2024

Der Megatrend Digitalisierung verändert den öffentlichen Verkehr nachhaltig. In immer mehr Aufgabenbereichen helfen elektronische Komponenten dabei, Abläufe zu verbessern und die Effizienz zu steigern. Das Schweizer Verkehrsunternehmen AAR bus+bahn digitalisiert nun auch die Arbeitsplätze seines Fahrpersonals.
Bitte mehr Zuversicht!
Authors: Frank Detlef
Published: June 2024

Man mag es schon bald nicht mehr hören: Begriffe wie Disruption (engl.: Auseinanderreißen, Zerbrechen), Transformation und Sharing Economy – alles am besten gleich 4.0 – begleiten einen Hype, der einerseits mit großen Erwartungen, andererseits oft mit erheblichen Befürchtungen einhergeht. – Ein Zwischenruf von Detlef Frank, Mitglied des Beirats der VDI-Gesellschaft Fahrzeug- und Verkehrstechnik.
Autobahngesellschaft und öffentlich-private Partnerschaft
Authors: Kossak Andreas
Published: June 2024

Das politische Gerangel um die Etablierung einer „Autobahngesellschaft“ und die Beteiligung Privater an der Finanzierung der Bundesfernstraßen sowie die Diskussionen um die Einführung einer „Ausländermaut“ für PKW tragen in mancher Hinsicht skurrile Züge. Eine Chronologie – und ein nachdrücklicher Appell zum Handeln.
Entwicklungstrends bei ausgewählten europäischen Fluggesellschaften
Authors: Kölker Katrin , Bießlich Steffen , Liebhardt Bernd , Lütjens Klaus , Gollnick Volker
Published: June 2024

Im folgenden Artikel werden für ausgewählte Fluggesellschaften Kennzahlen ermittelt und deren Entwicklung der letzten zehn Jahre nachverfolgt. Die Kennzahlen decken einen großen Bereich des Betriebs einer Fluggesellschaft ab und umfassen neben Bestandsgrößen auch angebotsseitige, finanzielle und geographische Aspekte. Die Analyse der verschiedenen Kennzahlen ermöglicht einen Überblick über deren spezifische Entwicklung im Zeitverlauf sowie einen Vergleich der Fluggesellschaften.
Mobilitätsmonitor Nr. 4 - April 2017
Authors: Bock Benno , Damrau Lena , Daniels Bert , Epp Julia , Hunsicker Frank , Nordhoff Sina , Scherf Christian , Schönduwe Robert , Stolte Benjamin , Toprani Vipul
Published: June 2024

Das Innovationszentrum für Mobilität und gesellschaftlichen Wandel (InnoZ) erstellt ein regelmäßiges Monitoring mit Umfeld- und „klassischen“ Verkehrsmarktdaten sowie ergänzenden Mobilitätsdaten zum Personenverkehr in Deutschland. Die Besonderheit ist die Verbindung unterschiedlicher Aggregationsebenen aus konventionellen Datenquellen und eigenen Erhebungsformen. Weitere Grafiken und Erläuterungen finden Sie unter www.innoz.de.
Digitalisierung - ein alter Hut?
Authors: Beims Martin , Fleischer Roland
Published: June 2024

Was bedeutet eigentlich Digitalisierung? Eine Befragung von zehn Managern würde höchstwahrscheinlich zehn verschiedene Antworten ergeben – stark abhängig davon, wie relevant der Befragte das Thema für das eigene Umfeld einschätzt. Ähnliches gilt für die Begriffe Industrie 4.0 und Big Data. Ignorieren Unternehmen die inzwischen unübersehbaren Entwicklungen bewusst? Und wie neu sind die Themen wirklich?
Reisezeiten und Stadtverkehrsplanung
Authors: Pez Peter , Janßen Antja
Published: June 2024

Reisezeitexperimente in Lüneburg, Hamburg und Göttingen zeigten, dass die Geschwindigkeitsrelationen von Verkehrsmitteln stark von den Grundstrukturen der Wegeführung und der Bevorrechtigung bzw. Benachteiligung abhängen. Eine Haushaltsbefragung zur Mobilität in Göttingen belegte, dass die realen Reisezeitrelationen sich in den subjektiven Einschätzungen wiederfinden. Die Beeinflussung der Reisezeiten bietet sich an, um via Verkehrsmittelwahl die Anteile am Modal Split in Richtung mehr Umwelt- und Sozialverträglichkeit zu steuern.
Transport for tomorow
Authors: Benezech Vincent
Published: June 2024

Transport will remain a growth industry. That also means it has to start tackling some serious challenges. An outlook by Vincent Benezech, Policy Analyst, International Transport Forum.
European passenger rail services in transition
Authors: Sippel Ludger , Nolte Julian
Published: June 2024

In December 2016, the European Parliament adopted the market pillar of the EU’s Fourth railway package. In combination with its technical pillar, the package aims at harmonising the EU railway policies for improving the competitiveness and attractiveness of railways and for a further development of the single European railway area [1]. This article describes the amendments of Regulation (EC) 1370/2007 by Regulation (EU) 2016/2338 and gives guidance to competent passenger rail authorities on the decisions to take for governing passenger rail services, the related tasks and their implications when it comes to organising and awarding a public service contract (PSC).
Using GPS technology for demand data collection
Authors: Baum Jakob , Howe Enrico
Published: June 2024

Travel demand data is a necessary basis for urban mobility planning, but especially in developing and emerging economies data availability is often weak or non-existing. The Global Positioning System (GPS) technology offers a cheap alternative for data collection to traditional diary or survey methods. This article elaborates on advantages and disadvantages of the approach. Also different aspects of the post-processing of GPS data in order to determine trips, mode choice and trip purposes are discussed. In practice, GIZ collects first experiences with the methodology in four Ukrainian cities.
Deutsche Bahn Group is shifting to the DB Enterprise Cloud
Authors: Dorn Bertram
Published: June 2024

The lack of IT standardization across subsidiaries, the complexity of organizational structures, and the high cost of maintaining legacy environments was hampering DB Group’s growth plans. The group was not as agile as competitors in rolling out new applications and improving the customer experience, which meant some of the subsidiaries were losing market share. Others even had initiated dangerous paths towards “shadow IT”. Thus, DB Systel contracted e.g. AWS to provide managed and unmanaged cloud services to the group and implemented a cloud-first strategy.
Carsharing in rural areas
Authors: Seemann Ann-Kathrin , Knöchel Sebastian
Published: June 2024

This article illustrates the concept of car sharing in rural areas, in particular the role of the municipalities. The qualitative study describes the state of research followed by the methodical approach and the results of the analysis which are visualized using a logic model. The results show that car sharing has further potential for growth in rural areas. In particular, municipal support, civil engagement and supra-regional subsidies play a key role in increasing the potential of this form of mobility in rural areas.
Das Thema Verkehr in den „Jamaika“-Koalitionsgesprächen auf Bundesebene
Authors: Kossak Andreas
Published: June 2024

Zu den strittigsten Themen der Verhandlungen um die Bildung einer „Jamaika-Koalition“ auf Bundesebene für die Legislaturperiode 2017-2021 gehörte der „Verkehr“. Dabei ging es allerdings im Kern nicht um Verkehr im sachlich adäquaten komplexen Wortsinn, sondern in erster Linie um Automobiltechnik unter dem Aspekt der Umweltverträglichkeit. Die Problematik in diesem Zusammenhang wäre heute nicht auch nur annähernd so brisant, wenn Politik, Industrie und Kommunen den Weg verfolgt hätten, der bereits vor über 40 Jahren als dringend geboten postuliert worden war. Punktuelle „Sofortprogramme“ mögen als Anstöße in die richtige Richtung geeignet sein; nachhaltige Lösungen sind jedoch nur durch ganzheitliche Ansätze mit realistischen Zeithorizonten und wirkungsvollen Kontrollmechanismen zu erreichen.
Digitaler Knoten 4.0
Authors: Engelmann Marc , Laux Philipp
Published: June 2024

Auf dem Testfeld AIM (Anwendungsplattform Intelligente Mobilität) in Braunschweig arbeitet ein Konsortium aus Wissenschaft und Industrie an dem Projekt „Digitaler Knoten 4.0“. Dabei wird die vernetzte, effiziente und sichere Steuerung von Mischverkehren, bestehend aus automatisierten und vernetzten Kraftfahrzeugen und konventionellen Verkehrsteilnehmern, an Kreuzungen erforscht. Die Ergebnisse sollen als Blaupause für zukünftige Mobilitätslösungen dienen. Neben technologischen Herausforderungen wirft das Projekt für die Beteiligten auch umfassende rechtliche Fragen für die Regelung des Kreuzungsverkehrs der Zukunft auf.
Evaluation eines Standortpotenzialmodells für E-Ladeinfrastruktur
Authors: Klein Timotheus , Scheler Christian
Published: June 2024

Ein wesentlicher Schritt zur Elektrifizierung des motorisierten Individualverkehrs besteht in der Bereitstellung einer angemessenen Ladeinfrastruktur. Die Freie und Hansestadt Hamburg hat frühzeitig mit der Installation von E-Ladesäulen begonnen, so dass nun Erfahrungswerte aus zwei Jahren vorliegen. Damit wurde das in Hamburg verwendete Standortpotenzialmodell evaluiert und weiter entwickelt. Es wird gezeigt, dass das verwendete Standortpotenzialmodell zweckmäßig ist und dass die Auslastung der Ladeinfrastruktur erheblich von einer deutlichen Kennzeichnung der betreffenden Parkstände abhängt.
Kritik der Reform der Bundesfernstraßenverwaltung
Authors: Kossak Andreas
Published: June 2024

Die Bundesfernstraßenverwaltung soll umfassend reformiert, Verwaltungs- und Finanzstrukturen neu geordnet werden. Großer Wurf oder Schritt in die falsche Richtung? Ein Kommentar von Dr.-Ing. Andreas Kossak, Planungsbüro Kossak Forschung & Beratung, Hamburg
Löst der indische Tiger den chinesischen Drachen ab?
Authors: Ruppik Dirk
Published: June 2024

Hat China als Treiber der Weltwirtschaft ausgedient – und übernimmt nun Indien diese Rolle? Im Land der Mitte lassen Prognosen zu sinkendem BIP-Wachstum, steigende Arbeitskosten und die langsamere Zunahme von Auslandsinvestitionen diese Vermutung aufkommen. Ist aber der Subkontinent bereit, die Führungsposition zu übernehmen? Obwohl durch neue Programme viel getan wird, lässt der Status Quo der Infrastruktur leider immer noch zu wünschen übrig.
Wirkungsweise der BahnCard aus Kunden- und Unternehmenssicht
Authors: Krämer Andreas
Published: June 2024

Die Wirkungsweise der BahnCard wird seit langem über einen Sunk Cost-Effekt erklärt: Kunden investieren in die Karte. Die Kartengebühren sind „verloren“, folglich ist nur der abgesenkte Ticketpreis für die Verkehrsmittelwahl entscheidungsrelevant. Die Bahn erreicht damit das Niveau der variablen Kosten des PKW und wird wettbewerbsfähig. Empirisch lässt sich die These allerdings nicht bestätigen. Offensichtlich greifen andere Mechanismen wie Precommitment, Vereinfachungsprozesse und die Affinität zur Bahn bzw. der Wunsch, die Bahn in Zukunft stärker zu nutzen.
Güterbahn nicht an die Wand fahren!
Authors: Kortschak Bernd H.
Published: June 2024

Die Güterbahn fährt mit 120 km/h Höchstgeschwindigkeit, der LKW mit 80 km/h. Und die Güterbahn kann, auf den Laufmeter bezogen, bis zum doppelten Volumen und bis zur dreifachen Nutzlast befördern. Dennoch gehen die Marktanteile trotz vieler Förderungen in Europa zurück. Das hat verschiedene Gründe – und kann zum Problem werden.
Kooperation TransRegio Alliance
Authors: Werdermann Georg
Published: June 2024

Für die Entwicklung ländlicher Räume ist eine gute Verkehrsanbindung mit Bus und Bahn wichtig. Allerdings sind in Schrumpfungsregionen und in wachsenden ländlichen Räumen im Umland von Metropolen unterschiedliche Ansätze gefragt. Interreg-Projekte bieten eine gute Möglichkeit, neue Lösungen zu testen, finanzielle Risiken zu senken und Entwicklungskosten durch das gegenseitige Lernen zu reduzieren. Die 2017 vom Deutschen Verband für Wohnungswesen, Städtebau und Raumordnung e.V. und der Gemeinsamen Landesplanungsabteilung Berlin-Brandenburg gegründete Kooperation „TransRegio Alliance“ möchte die verkehrliche Anbindung der ländlichen Regionen untereinander sowie an das europäische Kernnetz stärken. Dazu arbeiten Akteure aus den fünf ostdeutschen Bundesländern zusammen.
Seattle macht das Spiel
Authors: Kossak Andreas
Published: June 2024

Wachsende Verkehrsströme, überforderte Infrastrukturen und hohe Schadstoffwerte stellen viele Städte vor immense Herausforderungen. Seattle im US-Bundesstaat Washington geht die Herausforderungen auf innovative und bemerkenswert „demokratische“ Weise an.
Renaissance der Transrapid-Technologie in China?
Authors: Schwolgin Armin F.
Published: June 2024

Die Chinesen wollen die vielfach verbreite Ansicht, die Magnetschwebetechnik sei auf dem Abstellgleis, widerlegen. Auch wenn die sogenannte Maglev in Schanghai seit vielen Jahren ein Schattendasein fristet, wurde weiter an der Technologie gearbeitet. Als Ergebnis sind Magnetschwebebahnen für Changsha und Peking entwickelt worden, die im Öffentlichen Personennahverkehr (ÖPNV) im Einsatz sind. Jetzt geht es um Magnetschwebezüge, die mindestens 600 km/h schnell sind. Damit soll eine Lücke zwischen den regulären Hochgeschwindigkeitszügen und dem Flugzeug geschlossen werden.